Keyphrases
Nanoparticles
100%
Inflammation
100%
Liver X Receptor
100%
AZD3965
27%
Liver
18%
Lipid Metabolism
18%
Mouse Model of Atherosclerosis
18%
Copolymer
9%
Receptor Targets
9%
Cholesterol
9%
Signaling Pathway
9%
Self-assembly
9%
Macrophages
9%
Adverse Effects
9%
Nanotherapeutics
9%
Heart Stroke
9%
Heart Attack
9%
Polyethylene Glycol
9%
PLGA-PEG
9%
Poly(lactide-co-glycolide)
9%
Intravenous Injection
9%
Receptor Signaling
9%
Inflammatory Factors
9%
Fluorescently Labeled
9%
Systemic Administration
9%
Potential Therapeutics
9%
CD68
9%
Colocalization
9%
Target Gene Expression
9%
Plaque Macrophages
9%
Hepatic Steatosis
9%
PLGA-PEG Nanoparticles
9%
Plaque
9%
Hepatic Lipid
9%
Macrophage Content
9%
Diblock
9%
Lipogenic Genes
9%
Anti-inflammatory Effect
9%
Total Triglyceride
9%
Liver Lipid Metabolism
9%
Plasma Lipids
9%
Nuclear Receptor
9%
Low-density Lipoprotein Receptor
9%
Pharmacology, Toxicology and Pharmaceutical Science
Nanoparticle
100%
Atherosclerosis
100%
Inflammation
100%
Liver X Receptor Agonist
100%
Liver X Receptor
70%
3 [3 [[2 Chloro 3 (Trifluoromethyl)benzyl](2 Diphenylethyl)amino]propoxy]phenylacetic Acid
30%
Mouse Model
20%
Polyethylene Glycol
20%
Heart Infarction
10%
Macrogol
10%
Adverse Event
10%
Polyglactin
10%
Copolymer
10%
Triacylglycerol
10%
Chlordane
10%
Hormone Receptor
10%
Antiinflammatory Activity
10%
Fatty Liver
10%
Systemic Administration
10%